Gilead Sciences (GILD) Competitors

Ligand Pharmaceuticals has a net margin of 67.88% compared to Gilead Sciences' net margin of -10.64%. Ligand Pharmaceuticals' return on equity of 20.06% beat Gilead Sciences' return on equity.

Ligand Pharmaceuticals presently has a consensus price target of $335.75, suggesting a potential upside of 13.97%. Gilead Sciences has a consensus price target of $158.04, suggesting a potential upside of 14.22%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

In the previous week, Gilead Sciences had 23 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 38 mentions for Gilead Sciences and 15 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.91 beat Ligand Pharmaceuticals' score of 0.39 indicating that Gilead Sciences is being referred to more favorably in the news media.

Ligand Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Gilead Sciences had 29 more articles in the media than Moderna. MarketBeat recorded 38 mentions for Gilead Sciences and 9 mentions for Moderna. Gilead Sciences' average media sentiment score of 0.91 beat Moderna's score of 0.48 indicating that Gilead Sciences is being referred to more favorably in the media.

Gilead Sciences currently has a consensus target price of $158.04, suggesting a potential upside of 14.22%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 33.46%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than Moderna.

Gilead Sciences has higher revenue and earnings than Moderna. Gilead Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences has a net margin of -10.64% compared to Moderna's net margin of -141.43%. Gilead Sciences' return on equity of -2.11% beat Moderna's return on equity.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences presently has a consensus target price of $158.04, indicating a potential upside of 14.22%. Regeneron Pharmaceuticals has a consensus target price of $793.74, indicating a potential downside of 1.21%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

In the previous week, Gilead Sciences had 2 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 38 mentions for Gilead Sciences and 36 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.91 beat Regeneron Pharmaceuticals' score of 0.55 indicating that Gilead Sciences is being referred to more favorably in the media.

Vir Biotechnology presently has a consensus price target of $20.63, indicating a potential upside of 123.21%. Gilead Sciences has a consensus price target of $158.04, indicating a potential upside of 14.22%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Gilead Sciences.

Vir Biotechnology has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Gilead Sciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

In the previous week, Gilead Sciences had 20 more articles in the media than Vir Biotechnology. MarketBeat recorded 38 mentions for Gilead Sciences and 18 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 0.91 beat Vir Biotechnology's score of -0.13 indicating that Gilead Sciences is being referred to more favorably in the news media.

Gilead Sciences has a net margin of -10.64% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of -2.11% beat Vir Biotechnology's return on equity.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.